Figure 3 : Apigenin reduced constitutive STAT3 phosphorylation, suppressed STAT3 nuclear localization and STAT3-luciferase reporter activity in melanoma cells.

From: Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma

Figure 3

Cells were treated with apigenin (A) at different concentrations for 24 h or (B) at 40 μM for different time periods as indicated. Then the expression levels of STAT3 and phospho-STAT3 were determined by the Western blot analysis. (C) Cells were treated with apigenin at various concentrations for 8 h and then the expressions of phospho-JAK2, JAK2, phospho-Src and Src were examined by Western blotting. (D) A375 cells were treated with 20 μM apigenin for 8 h, and then analyzed for the intracellular distribution of STAT3 by immunocytochemistry. (E) A375 cells were transfected with a STAT3-luciferase reporter plasmid together with a PRL-CMV construct for 12 h, followed by treatment with indicated concentrations of apigenin for another 12 h, and then the STAT3 transcriptional activity was measured by the dual-luciferase reporter assay. Data were shown as mean ± SD from three independent experiments, *P < 0.05 and **P < 0.01.